This is a phase II study to assess the role of tumor histogenesis (subtype), FDG-PET and SC-EPOCH-RR in newly diagnosed HIV-associated CD20+ diffuse large B-cell lymphoma. Patients received a minimum of 3 and maximum of 6 cycles with one cycle beyond stable radiographic and FDG-PET scans. Overall, 79% of patients received 3 cycles. Combination anti-retroviral therapy was suspended before and resumed after therapy. Thirty-three enrolled patients had a median age of 42 years (range 9-61) and 76% had a high-intermediate or high age-adjusted international prognostic index. At 5 years median follow-up, progression-free and overall survival were 84% and 68%, respectively. There were no treatment related deaths or new opportunistic infections during treatment and patients had sustained CD4 cell count recovery and HIV viral control following treatment. FDG-PET after 2 cycles had an excellent negative but poor positive predictive value. Tumor histogenesis was the only characteristic associated with lymphoma-specific outcome with 95% of Germinal Center B-cell (GCB) versus 44% of non-GCB DLBCL progression-free at 5 years. SC-EPOCH-RR is highly effective and less immunosuppressive with shorter duration therapy compared to standard strategies. However, new therapeutic advances are needed for non-GCB
Introduction
The survival of acquired immunodeficiency syndrome-related lymphoma (ARL) has significantly improved over the past decade, but it has been mostly attributed to HIV control and not to advances in lymphoma treatment [1] [2] [3] [4] [5] [6] . We tested a strategy based on the da-EPOCH (dose adjusted; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) regimen which balanced the competing needs of lymphoma treatment and HIV management 7 . This regimen employed dose adjustment based on the degree of immune suppression and temporarily suspended combination antiretroviral therapy (cART) to obviate untoward drug interactions 8 . da-EPOCH proved to be highly effective with a progression-free (PFS) and overall survival (OS) of 73% and 60%, respectively, at 53 months in ARL, the majority of which were DLBCL 7 . Baseline CD4+ cells ≤ 100/μl was the only biomarker of decreased survival in a multivariate analysis and patients in remission had significant recovery of immune function and HIV control. Based on these results, da-EPOCH has been identified as a treatment of choice for ARL 5, 9 .
Herein, we report results on a second generation regimen which aimed to improve efficacy and decrease toxicity through the addition of dose dense rituximab to EPOCH.
The design was based on the hypothesis that rituximab would significantly enhance the efficacy of chemotherapy, thereby allowing a major reduction in the number of treatment cycles 10 . Interestingly, years after our study commenced, a phase III study of CHOP ± rituximab concluded that rituximab did not improve the outcome of ARL and was potentially unsafe in immune compromised patients 4 . As we show below, however, our present study does not support these conclusions.
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A novel component of the present study was the use of sequential fluorodeoxyglucose positron emission tomography (FDG-PET) to assess early and late responses in HIVassociated DLBCL. Furthermore, this study actively employed interim FDG-PET in the decision to reduce the number of treatment cycles. Our goal was to study for the first time whether DLBCL could be effectively treated with up to fifty percent fewer cycles than a standard course and to assess the role and specificity and sensitivity of FDG-PET in HIV-associated DLBCL.
We also wished to examine the role of tumor biology in the outcome of HIV-associated DLBCL. While studies have assessed histology and CD4 cell count, none have prospectively assessed molecular histogenesis of DLBCL which derive from a germinal center or an activated B-cell (GCB or ABC) and are independently prognostic in HIV negative DLBCL [11] [12] [13] . Importantly, insight into the molecular basis of treatment failure is critical to the development of more effective treatments in HIV-associated DLBCL.
Thus, we wished to assess if tumor histogenesis is a major factor in lymphoma-specific survival and if one or both molecular subtypes might benefit from additional novel interventions.
Methods

Patients
Forty-five patients with untreated CD20+ ARL entered on a study of short course EPOCH and dose dense rituximab at the National Cancer Institute. Thirty-five patients had DLBCL and 10 patients with Burkitt lymphoma will be reported separately. Two 
Evaluation and Treatment
Evaluation included routine blood tests, imaging (CT body, MRI brain and FDG-PET), bone marrow biopsy and lumbar puncture with cytology and flow cytometry. Serial plasma HIV-1 viral loads (mRNA copies/ml plasma) were measured by the RocheAmplicor® method and T-lymphocyte subsets were determined by flow cytometry at baseline and end of SC-EPOCH-RR and every 3-6 months thereafter.
The study was designed to administer one cycle beyond no significant radiographic changes for a minimum of 3 and maximum of 6 cycles. cART was suspended before SC-EPOCH-RR and reinstated on day 6 of the last cycle. Response was based on serial CT body and FDG-PET scans beginning at cycle three day 1 and performed after each cycle thereafter until treatment completion (Figure 1) . Thus, the number of scans performed was the same as the number of cycles received for each patient. In clinical practice, however, the post-treatment scans could be omitted if the previous scans were 6 negative. SC-EPOCH-RR was stopped when there was < 25% reduction in bidimensional products compared to the previous interim CT scan and the standardized uptake values (SUV) on FDG-PET decreased > 50% compared to the pre-treatment FDG-PET. This definition was developed to take into account HIV-associated reactive changes that may confound FDG-PET interpretations. Response designation followed the International Workshop criteria (before CIV began) and on day 5 (after CIV completed and before cyclophosphamide).
All patients received filgrastim 300 μg SQ (pediatric dose 5 μg/kg/day-maximum 300 μg/day) from day 6 until absolute neutrophil count (ANC) ≥ 5000 cells/mm 3 
FDG-PET Imaging
Patients fasted for 6 hours prior to FDG-PET and injected with a nominal amount of 
Statistical Analysis
The primary endpoint was to test the hypothesis that the number of chemotherapy cycles could be reduced from a standard of 6 cycles 7, 20 . Based on a mean of 4 cycles, the study would have an 80% power at 0.05 two-sided significance to detect a difference between a mean of 4 and 5 cycles with 1.5 standard deviation in 28 patients.
Upon completion of accrual for the primary endpoint, enrollment was increased to more fully address the secondary endpoints of FDG-PET and immune recovery. Assessment of tumor histogenesis and EBV was obtained from standard immunohistochemical panels.
PFS and OS were determined from on-study until death, progression, or last follow-up by the Kaplan-Meier method and statistical significance was determined by a log-rank test. For PFS, deaths unrelated to acute treatment or lymphoma were censored. Death within 30 days of chemotherapy was defined as treatment related. For PFS, KaplanMeier curves were developed for all prognostic factor analyses. An exact log-rank test was used to determine the impact of tumor histogenesis (GCB versus non-GCB) on PFS since there were so few failures in one group. For univariate prognostic factors analyses, if patients were grouped into two categories after preliminary evaluation of 3 categories, the subsequent p-value was adjusted by multiplying the unadjusted p-value by two. This would account for the implicit testing which resulted in a decision to place 
Results
Patient Characteristics
Thirty-three patients with untreated DLBCL were enrolled. They had a median age of 42 years and 76% had a high age-adjusted international prognostic index (IPI) ( Table 1) Toxicity was evaluable on all 109 cycles of treatment. Hematological toxicity included neutropenia < 500 cells/mm 3 on 46% and thrombocytopenia < 50,000/mm 3 on 33% of cycles. Febrile neutropenia occurred on 31% of cycles, no new opportunistic infections were observed on treatment and there were no treatment related deaths. Nonhematological toxicity was similar to our report of da-EPOCH 7 .
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FDG-PET Scans
FDG-PET scan after 2 cycles had an excellent negative predictive value and was not significantly different from the post-therapy scan ( Table 2 ). The positive predictive value of FDG-PET scans was quite poor, however, presumably due to a high rate of HIVassociated reactive changes. Hence, FDG-PET had a poor sensitivity and specificity for HIV-associated DLBCL when interpreted using commonly recommended criteria 19 .
HIV and CD4 T-cell Dynamics
A unique aspect of our strategy is suspension of cART during treatment to obviate adverse effects on the lymphoma treatment 2, 7 . We previously demonstrated this approach led to reversible viral load increase and CD4 cell decrement and excellent disease control with da-EPOCH 
Tumor Biology and Prognostic Models
GCB and non-GCB DLBCL subtypes comprised 72% and 28% of cases, respectively, and EBV expression was detected in 31% of cases (Table 1) . EBV expression was detected somewhat more frequently in the non-GCB (4/7; 57%) compared to GCB (Figure 4 ).
To examine the role of GCB versus non-GCB histogenesis in the outcome of HIVassociated DLBCL, we developed prognostic models based on characteristics in Table   1 . In the univariate analysis, only tumor histogenesis was associated with PFS ( Figure   2C ), whereas tumor histogenesis, EBV and CD4 cell count were all associated with OS ( Figures 2D, 2F 
Discussion
Treatment of ARL presents the dual challenge of achieving tumor control while maintaining immune integrity. Though conventional wisdom argues for maintaining cART during lymphoma treatment to minimize the risks of uncontrolled HIV replication, we have hypothesized that the unpredictable effects of cART on chemotherapy pharmacokinetics and pharmacodynamics and lymphocyte apoptosis may reduce cure 7, 8 . While it is established that structured cART suspension increases AIDSassociated events, a large randomized study showed it required a mean (range) of 16.8 . Furthermore, we previously showed recovery of immune function, HIV viral control and reversion to wild type virus following reinstitution of cART after da-EPOCH chemotherapy 7 .
We believe our current results provide further evidence for the safety of cART suspension. Indeed, only three patients died in remission from HIV-associated infections and in all cases, the infection(s) were preexistent and the patients were severely immune compromised and cART resistant. Furthermore, only two of these cases were immediately after completing chemotherapy treatment and occurred despite active treatment for their infections. Hence, there is no scientific basis to associate
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The present study extends our findings with da-EPOCH through reducing chemotherapy cycles by half with a reduction in cART suspension from 16 to 7 weeks. To achieve this, several modifications were made to da-EPOCH. First, we removed dose adjustment based on initial CD4 cell counts due to the improvement in HIV natural history; thus patients received full dose EPOCH on cycle one with subsequent reductions based on hematological toxicity. We also incorporated dose dense rituximab on day 1 and 5 of each cycle. When we developed SC-EPOCH-RR 9 years ago, we hypothesized that rituximab would be beneficial and that dose dense administration would significantly increase drug exposure; it had been shown that rituximab T ½ doubled and Cmax increased 50% between the first and fourth dose on a standard weekly schedule 22 . We also restricted the present study to DLBCL to reduce the confounding effects associated with the biological diversity of ARL.
Using a combination of CT and FDG-PET response criteria, most patients (79%) received 3 cycles of SC-EPOCH-RR. Overall, 91% of patients achieved CR, and 84% are progression-free and 68% are alive at five years. SC-EPOCH-RR had significantly less immune toxicity than da-EPOCH, which was administered for six cycles, and achieved excellent immune reconstitution and HIV control following reinstitution of cART; similar to those findings when chemotherapy is administered with cART 23 . The survival outcomes compare favorably with da-EPOCH where PFS and OS were 73%
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From and 60%, respectively, at 53 months suggesting dose-dense rituximab may be beneficial, although the study was not designed to address this question 7 . Our results appear to be significantly better than those achieved in a phase III study of CHOP± rituximab, which reported 50% TTP (comparable to PFS in the present study) and OS with R-CHOP at 2.4 years 4 . Importantly, our results do not support that trials' conclusion that rituximab may be risky as we observed no treatment related deaths 20, 24 .
While SC-EPOCH-RR was associated with greater hematological toxicity than da-EPOCH, likely due to higher chemotherapy dose intensity, we did not encounter any treatment related deaths 7 .
The efficacy and safety of EPOCH and rituximab is further supported by preliminary results from the randomized phase II trial of concurrent versus sequential rituximab with da-EPOCH in ARL from the AIDS Malignancy Consortium (AMC) Trial 034 25 . The AMC study, based on da-EPOCH and unpublished results from the present study, aimed to assess if the complete response (CR) rate of da-EPOCH and rituximab was likely to be superior to historical results with CHOP±R; and if da-EPOCH with concurrent versus sequential rituximab was more toxic and/or more effective 4, 7, 25, 26 . Preliminary results found no increase in toxicity between the arms and rejected the null hypothesis of 50% (associated with CHOP±R) in favor of 75% CR for da-EPOCH with concurrent rituximab (P = 0.005; power 0.89) 4, 25 . These results provide additional evidence that rituximab does not increase chemotherapy toxicity and that da-EPOCH with concurrent rituximab is likely to be more effective than R-CHOP.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From To our knowledge, this is the first study to employ interim FDG-PET in a treatment paradigm to reduce chemotherapy cycles in DLBCL, and provides a unique opportunity to study its utility in HIV-associated lymphomas. This is particularly important because HIV-associated nodal reactive hyperplasia and infections may confound FDG-PET interpretations 27, 28 . To assess the value of FDG-PET, they were blindly interpreted employing commonly accepted criteria 19 . FDG-PET obtained after 2 cycles and at the end of therapy showed a high negative predictive value of 91% and 87%, respectively, but a poor positive predictive value of 15% and 7%, respectively. It was difficult to differentiate low level FDG-PET inflammatory from active lymphoma. Indeed, 65% of FDG-PET scans were positive after cycle 2 and yet few of these patients relapsed.
Though the role of FDG-PET needs further study in ARL, it is likely to remain highly problematic.
Numerous studies have identified IPI and CD4 cell counts as the important predictors of ARL outcome in the post-cART era 4, 6, 7 . Indeed, there has been some concern that withholding cART during chemotherapy will promote CD4 cell loss and decrease both HIV and lymphoma-specific survival. While there is ample evidence that ARL pathogenesis is influenced by immune status, there is no scientific evidence or rationale that treatment sensitivity of established lymphomas are dependent on the CD4 cell count 13 . To help address this issue, we analyzed clinical and biological markers of outcome in our study. Unlike other studies, no clinical prognostic characteristics including IPI were associated with PFS or OS. Only tumor histogenesis was significantly associated with lymphoma-specific outcome with 95% of GCB and 44% of non-GCB DLBCL progression-free at 5 years. Furthermore, both tumor histogenesis and CD4 cell count were independently associated with survival, reflecting both lymphoma and HIV-specific deaths. These results mirror the importance of tumor histogenesis in the outcome of HIV-negative DLBCL 11, 12, 29 . We also examined the relationship between tumor histogenesis, immune status and EBV expression and found an association, albeit a trend, between non-GCB tumor cell type and lower CD4 cell counts and EBV expression, suggesting a role for immune status in pathogenesis. It is important to recognize the potential limitations of IHC determination of tumor histogenesis. As validation for our methods, we previously showed full concordance between IHC and gene expression profiling, the gold standard, in 12 biopsies of DLBCL 18, 30, 31 .
Our results show for the first time that tumor biology is the major factor in lymphomaspecific survival in HIV-associated DLBCL. In contrast, a recent publication from the AMC found no relationship between tumor histogenesis or EBV infection and outcome in HIV associated DLBCL, which is contrary to our own results and numerous publications in HIV negative DLBCL 11, 12, 18, 29, 32 . Several factors may explain these negative findings. Firstly, the AMC study was retrospective and included biopsy specimens from two different studies and four different treatment regimens; CHOP±R and EPOCH with concurrent or sequential rituximab. This is likely to confound the results because rituximab and the chemotherapy platform (CHOP versus EPOCH) appear to influence the impact of tumor histogenesis on outcome 11, 12, 29 . These results are further limited by the relatively short and variable follow-up in the two studies.
Secondly, the outcome measures did not distinguish lymphoma-specific survival from overall survival and thus may be confounded by a high rate of non-lymphoma-specific deaths. Thirdly, the accuracy of immunohistochemical determination of tumor histogenesis can be highly variable and validation of the laboratory technique against gene expression profiling is an important control 30, 31 .
Understanding the relationship of tumor biology to outcome is important for the identification of molecular targets and improvement of therapy. Our present finding that SC-EPOCH-RR is curative in nearly all cases of GCB DLBCL is similar to our results in HIV negative cases (unpublished observations) 29, 33 . In vitro, sustained exposure of tumor cells to topoisomerase II inhibition by etoposide and low-dose doxorubicin promote the p53-p21 pathway and activates the check-point kinase (Chk2) independently of ATR, pathways that are associated with the GCB Bcl-6 transcription factor 34, 35 . Such studies indicate that prolonged exposure to topoisomerase II inhibition, as achieved with EPOCH, may be particularly effective in GCB DLBCL. In contrast, our results indicate that therapeutic advances are needed in non-GCB DLBCL, similar to findings in HIV negative non-GCB DLBCL 11, 29 . In HIV-negative DLBCL, the majority of cases identified as non-GCB by immunohistochemistry have an ABC DLBCL gene expression profile 18 . The poor outcome of non-GCB (ABC) DLBCL may be related to the constitutive activation of the NF-kB pathway which has been ascribed to activity of a signaling cascade involving CARD11, BCL-10 and MALT1 leading to activation of IkB kinase [36] [37] [38] . Furthermore, inhibition of NF-kB in ABC DLBCL cell lines is toxic, in keeping with the ability of this pathway to inhibit apoptosis 36, 39 . Clinically, it has been For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
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shown that the combination of EPOCH with the proteasome inhibitor bortezomib, which can inhibit NF-κB through blocking IκBα degradation, had significantly greater benefit in recurrent ABC versus GCB DLBCL; a strategy which may improve the outcome of untreated ABC DLBCL 30 .
In conclusion, most HIV associated DLBCL are curable with three cycles of SC-EPOCH-RR and tumor histogenesis is the most important determinant of lymphomaspecific survival. While FDG-PET is useful when used alongside CT scans to determine when treatment is completed, they should be used with caution in HIV-associated DLBCL. These results suggest that SC-EPOCH-RR is an important advance for HIVassociated DLBCL, although AIDS related deaths and non-GCB DLBCL remain important barriers to overall survival. The authors made the following contributions: Kieron Dunleavy-study conduct, analysis and writing; Richard F. Little-study design, conduct; Stefania Pittaluga-study anaylsis;
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